OBJECTIVE: To assess the natural story of HIV-associated affective and cognitive disorders and the relationship with clinical, pharmacological, immunological and behavioural factors. METHOD: A total of 395 HIV-positive patients, naive to Highly Active Antirectroviral therapy (HAART), with no severe psychiatric disorders have been enrolled in the Neuro-ICONA Study. All participants were administered a comprehensive data collection instrument including an addiction behaviour survey, a medical problem list, a psychiatric assessment, a validated neuropsychological test battery. RESULTS: The global prevalence of cognitive impairment and of prominent depressive symptomatology were 17.9 and 15.5%, respectively. A significant difference in the prevalence of prominent depressive symptomatology was observed between patients in HAART and those not taking HAART(14.1 vs. 23.8%; P = 0.05). CONCLUSION: Depressive and cognitive disorders affect a substantial proportion of HIV-seropositive subjects. The prevalence of prominent depressive symptomatology appears to significantly vary in relationship to the therapeutic protocol.
OBJECTIVE: To assess the natural story of HIV-associated affective and cognitive disorders and the relationship with clinical, pharmacological, immunological and behavioural factors. METHOD: A total of 395 HIV-positive patients, naive to Highly Active Antirectroviral therapy (HAART), with no severe psychiatric disorders have been enrolled in the Neuro-ICONA Study. All participants were administered a comprehensive data collection instrument including an addiction behaviour survey, a medical problem list, a psychiatric assessment, a validated neuropsychological test battery. RESULTS: The global prevalence of cognitive impairment and of prominent depressive symptomatology were 17.9 and 15.5%, respectively. A significant difference in the prevalence of prominent depressive symptomatology was observed between patients in HAART and those not taking HAART(14.1 vs. 23.8%; P = 0.05). CONCLUSION:Depressive and cognitive disorders affect a substantial proportion of HIV-seropositive subjects. The prevalence of prominent depressive symptomatology appears to significantly vary in relationship to the therapeutic protocol.
Authors: Sarah Tymchuk; Daniela Gomez; Noshin Koenig; M John Gill; Esther Fujiwara; Christopher Power Journal: Can J Psychiatry Date: 2017-12-11 Impact factor: 4.356
Authors: Reuben N Robbins; Robert H Remien; Claude A Mellins; John A Joska; Dan J Stein Journal: AIDS Patient Care STDS Date: 2011-09-15 Impact factor: 5.078
Authors: Noeline Nakasujja; Richard L Skolasky; Seggane Musisi; Peter Allebeck; Kevin Robertson; Allan Ronald; Elly Katabira; David B Clifford; Ned Sacktor Journal: BMC Psychiatry Date: 2010-06-10 Impact factor: 3.630
Authors: Michael J Silverberg; Mary Elizabeth Gore; Audrey L French; Monica Gandhi; Marshall J Glesby; Andrea Kovacs; Tracey E Wilson; Mary A Young; Stephen J Gange Journal: Clin Infect Dis Date: 2004-08-16 Impact factor: 9.079
Authors: April D Thames; Jennifer Moizel; Stella E Panos; Sapna M Patel; Desiree A Byrd; Hector F Myers; Gail E Wyatt; Charles H Hinkin Journal: AIDS Patient Care STDS Date: 2012-08-13 Impact factor: 5.078